Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jan;7(1):43-53.
doi: 10.1038/nrendo.2010.196. Epub 2010 Nov 30.

Testicular germ cell tumors: pathogenesis, diagnosis and treatment

Affiliations
Review

Testicular germ cell tumors: pathogenesis, diagnosis and treatment

Christian Winter et al. Nat Rev Endocrinol. 2011 Jan.

Abstract

Testicular germ cell tumors represent the most common solid malignancy of young men aged 15-40 years. Histopathologically, testicular germ cell tumors are divided into two major groups: pure seminoma and nonseminoma. The pathogenesis of testicular germ cell tumors remains unknown; however, cryptorchidism is the main risk factor, and molecular studies have shown strong evidence of an association between genetic alterations and testicular germ cell tumors. In cases of suspicion for testicular germ cell tumor, a surgical exploration with orchiectomy is obligatory. After completion of diagnostic procedures, levels of serum tumor markers and the clinical stage based on the International Union Against Cancer tumor-node-metastasis classification should be defined. Patients with early-stage testicular germ cell tumors are treated by individualized risk stratification within a multidisciplinary approach. The individual management (surveillance, chemotherapy or radiotherapy) has to be balanced according to clinical features and the risk of short-term and long-term toxic effects. Treatment for metastatic tumors is based on risk stratification according to International Germ Cell Cancer Collaborative Group classification and is performed with cisplatin-based chemotherapy and residual tumor resection in cases of residual tumor lesion. High-dose chemotherapy represents a curative option for patients with second or subsequent relapses.

PubMed Disclaimer

References

    1. World J Urol. 2009 Aug;27(4):463-70 - PubMed
    1. Clin Oncol (R Coll Radiol). 1998;10(4):237-41 - PubMed
    1. BJU Int. 2007 May;99(5):993-7 - PubMed
    1. BJU Int. 2009 Nov;104(9 Pt B):1413-7 - PubMed
    1. J Urol. 2008 Mar;179(3):936-40; discussion 940 - PubMed

MeSH terms